Evidence map›Paper›PMID 41909045›Full record

Trial reportFrontiers in nutrition2026

Potential lipid-lowering effects of

Supawan Buranapin, Atcharaporn Ontawong, Chutima S Vaddhanaphuti, Piti Inthaphan, Jakkapong Inchai, Thanthakan Saithong, Kanjana Narkprasom, Varunya Fuangchoom, Doungporn Amornlerdpison

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Supawan Buranapin *Section of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Atcharaporn Ontawong *Division of Physiology, School of Medical Sciences, University of Phayao, Phayao, Thailand.
Chutima S VaddhanaphutiInnovative Research Unit of Epithelial Transport and Regulation (iETR), Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Piti InthaphanSection of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Jakkapong InchaiInnovative Research Unit of Epithelial Transport and Regulation (iETR), Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Thanthakan SaithongInnovative Research Unit of Epithelial Transport and Regulation (iETR), Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Kanjana NarkprasomFaculty of Engineering and Agro-Industry, Maejo University, Chiang Mai, Thailand.
Varunya FuangchoomGraduate Program in Food Engineering, Faculty of Engineering and Agro-Industry, Maejo University, Chiang Mai, Thailand.
Doungporn AmornlerdpisonCenter of Excellence in Agricultural Innovation for Graduate Entrepreneur, Maejo University, Chiang Mai, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Seventy-nine obese men and women [BMI ≥ 25 kg/m Results: Within-group analysis showed a significant reduction of LDL-C, triglyceride (TG), and total cholesterol (TC) levels by 14.9, 18.9, and 8.0%, respectively, while increasing high-density lipoprotein cholesterol (HDL-C) levels by 6.0% in the CPE product group compared to baseline after 24 weeks of intervention. In the placebo group, LDL-C and HDL-C levels decreased significantly by 7.7 and 5.3%, respectively, at week 24, but TC and TG levels did not change significantly. After adjustment for screening lipid values, the CPE group showed greater reductions in total cholesterol, triglycerides, and LDL-C than the placebo group (-6.3% vs. -2.4%, Conclusion: This study suggests that the CPE product could be a nutraceutical product option for lowering lipids in hyperlipidemic patients. However, this study has limitations, including the short treatment period, the small number of enrolled participants, and its exploratory nature. Clinical trail registration: This study was registered at the Thai Clinical Trial Registry with the identification number 20241117005. https://www.thaiclinicaltrials.org/.

Indexed as

coffee pulp aqueous extractCPE producthyperlipidemialipid profilesobese

Identifiers

PMID41909045
PMCPMC13017307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.